Tech trends: Cybercrime and small caps
Technology has been a driving force in equity markets over the last 12 months but the sector continues to divide investors. Watch Ali Unwin discuss what he believes are some of the most common misconceptions when it comes to investing in technology.
Actions speak louder than words: Fixed income at Capital Group
Capital Group might not be widely known for fixed income in the UK. However, with over 45 years of managing fixed income investments across developed and emerging markets, governments and corporates, there’s more to this investment management company than meets the eye, says Jeremy Cunningham, a Capital Group fixed income investment director.
Biotech outlook: Increasing strength of innovation in 2018
2018 should be another intensive year for BB Biotech, with many important clinical trial results and regulatory approvals expected to keep the biotechnology industry and our holdings in focus. We continue to expect new product launches and their uptake in the market to accelerate the already positive underlying growth in revenues and cash flows experienced by the industry and companies in our portfolio.
Strength in efficiency
With high levels of demand and limited access, the challenges facing India’s healthcare system are not too dissimilar to other emerging markets (EM). However, its strengths in tackling problems such as bed shortages may be providing valuable lessons for more developed market.
BB Biotech – double digit return and record dividend
With a total return of 23.1% in CHF BB Biotech delivered a strong performance in 2017. A record regular dividend of CHF 3.30 per share will be proposed at the AGM.